{
    "id": 3247,
    "name": "rhabdomyosarcoma",
    "source": "DOID",
    "definition": "A skeletal muscle cancer that arise from skeletal muscle progenitors. [url:http\\://en.wikipedia.org/wiki/Rhabdomyosarcoma]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:3247",
    "evidence": [
        {
            "id": 444,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) inhibited tumor growth in a mouse model of rhabdomyosarcoma expressing mutated FGFR4 (PMID: 24124571).",
            "molecularProfile": {
                "id": 633,
                "profileName": "FGFR4 mutant"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3247,
                "name": "rhabdomyosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 88,
                    "pubMedId": 24124571,
                    "title": "Targeting wild-type and mutationally activated FGFR4 in rhabdomyosarcoma with the inhibitor ponatinib (AP24534).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24124571"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1327,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, rhabdomyosarcoma cells over expressing FGFR4 activating mutations demonstrated increased sensitivity to Iclusig (ponatinib), resulting in decreased tumor cell growth in culture and in cell line xenograft models (PMID: 24124571).",
            "molecularProfile": {
                "id": 1220,
                "profileName": "FGFR4 act mut"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3247,
                "name": "rhabdomyosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 88,
                    "pubMedId": 24124571,
                    "title": "Targeting wild-type and mutationally activated FGFR4 in rhabdomyosarcoma with the inhibitor ponatinib (AP24534).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24124571"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2059,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, rhabdomyosarcoma cells over expressing FGFR4 had increased sensitivity to Iclusig (ponatinib), resulting in decreased cell growth in culture (PMID: 24124571).",
            "molecularProfile": {
                "id": 2409,
                "profileName": "FGFR4 over exp"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3247,
                "name": "rhabdomyosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 88,
                    "pubMedId": 24124571,
                    "title": "Targeting wild-type and mutationally activated FGFR4 in rhabdomyosarcoma with the inhibitor ponatinib (AP24534).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24124571"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2063,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Selumetinib (AZD6244) and AZD8055 worked synergistically to inhibit tumor growth in xenograft models of rhabdomyosarcoma (PMID: 23918606).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2561,
                "therapyName": "AZD8055 + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 3247,
                "name": "rhabdomyosarcoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 2538,
                    "pubMedId": 23918606,
                    "title": "Dual blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) pathways synergistically inhibits rhabdomyosarcoma cell growth in vitro and in vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23918606"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 3942,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BMS-754807 treatment resulted in significant tumor growth delay in 33% (2/6) of cell line xenograft models of rhabdomyosarcoma (PMID: 21298745).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 686,
                "therapyName": "BMS-754807",
                "synonyms": null
            },
            "indication": {
                "id": 3247,
                "name": "rhabdomyosarcoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4302,
                    "pubMedId": 21298745,
                    "title": "Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21298745"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 4146,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, a trial arm assessing Sprycel (dasatinib) in rhabdomyosarcoma patients (n=13) was suspended due to lack of drug activity (PMID: 26710211).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3247,
                "name": "rhabdomyosarcoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4408,
                    "pubMedId": 26710211,
                    "title": "SARC009: Phase 2 study of dasatinib in patients with previously treated, high-grade, advanced sarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26710211"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5316,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of YM155 and Platinol (cisplatin) inhibited tumor growth in a human rhabdomyosarcoma cell line xenograft model (PMID: 26983495).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3829,
                "therapyName": "Cisplatin + YM155",
                "synonyms": null
            },
            "indication": {
                "id": 3247,
                "name": "rhabdomyosarcoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5013,
                    "pubMedId": 26983495,
                    "title": "Survivin selective inhibitor YM155 promotes cisplatin\u2011induced apoptosis in embryonal rhabdomyosarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26983495"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5452,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LLL12 inhibited Stat3 signaling and cell proliferation of rhabdomyosarcoma cell lines demonstrating constitutive Stat3 activation in culture (PMID: 21109950).",
            "molecularProfile": {
                "id": 20856,
                "profileName": "STAT3 positive"
            },
            "therapy": {
                "id": 3592,
                "therapyName": "LLL12",
                "synonyms": null
            },
            "indication": {
                "id": 3247,
                "name": "rhabdomyosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5065,
                    "pubMedId": 21109950,
                    "title": "Two small molecule compounds, LLL12 and FLLL32, exhibit potent inhibitory activity on STAT3 in human rhabdomyosarcoma cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21109950"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5455,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, FLLL32 inhibited Stat3 signaling and cell proliferation in rhabdomyosarcoma cell lines demonstrating constitutive Stat3 activation in culture (PMID: 21109950).",
            "molecularProfile": {
                "id": 20856,
                "profileName": "STAT3 positive"
            },
            "therapy": {
                "id": 3862,
                "therapyName": "FLLL32",
                "synonyms": null
            },
            "indication": {
                "id": 3247,
                "name": "rhabdomyosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5065,
                    "pubMedId": 21109950,
                    "title": "Two small molecule compounds, LLL12 and FLLL32, exhibit potent inhibitory activity on STAT3 in human rhabdomyosarcoma cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21109950"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7018,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SANT1 inhibited survival of rhabdomyosarcoma cells with elevated GLI2 and SHH mRNA levels in culture (PMID: 26781311).",
            "molecularProfile": {
                "id": 24358,
                "profileName": "GLI2 over exp SHH over exp"
            },
            "therapy": {
                "id": 3990,
                "therapyName": "SANT1",
                "synonyms": null
            },
            "indication": {
                "id": 3247,
                "name": "rhabdomyosarcoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6046,
                    "pubMedId": 26781311,
                    "title": "Targeting hedgehog signaling pathway in pediatric tumors: in vitro evaluation of SMO and GLI inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26781311"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7024,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GANT61 inhibited survival of rhabdomyosarcoma cells with elevated GLI2and SHH mRNA levels in culture (PMID: 26781311).",
            "molecularProfile": {
                "id": 24358,
                "profileName": "GLI2 over exp SHH over exp"
            },
            "therapy": {
                "id": 1786,
                "therapyName": "GANT61",
                "synonyms": null
            },
            "indication": {
                "id": 3247,
                "name": "rhabdomyosarcoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6046,
                    "pubMedId": 26781311,
                    "title": "Targeting hedgehog signaling pathway in pediatric tumors: in vitro evaluation of SMO and GLI inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26781311"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8324,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, JQ1 treatment resulted in cytostatic effects in patient-derived rhabdomyosarcoma cell lines in culture, but inhibited tumor growth in patient-derived xenograft models due to inhibition of tumor angiogenesis (PMID: 26908627).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1574,
                "therapyName": "JQ1",
                "synonyms": null
            },
            "indication": {
                "id": 3247,
                "name": "rhabdomyosarcoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6610,
                    "pubMedId": 26908627,
                    "title": "The Bromodomain BET Inhibitor JQ1 Suppresses Tumor Angiogenesis in Models of Childhood Sarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26908627"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8392,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, rhabdomyosarcoma cells over expressing FGFR4 N535K demonstrated increased sensitivity to Iclusig (ponatinib), resulting in decreased tumor cell growth in culture and in cell line xenograft models (PMID: 24124571).",
            "molecularProfile": {
                "id": 4322,
                "profileName": "FGFR4 N535K"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3247,
                "name": "rhabdomyosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 88,
                    "pubMedId": 24124571,
                    "title": "Targeting wild-type and mutationally activated FGFR4 in rhabdomyosarcoma with the inhibitor ponatinib (AP24534).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24124571"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8393,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, rhabdomyosarcoma cells over expressing FGFR4 V550E demonstrated increased sensitivity to Iclusig (ponatinib), resulting in decreased tumor cell growth in culture and in cell line xenograft models (PMID: 24124571).",
            "molecularProfile": {
                "id": 4323,
                "profileName": "FGFR4 V550E"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3247,
                "name": "rhabdomyosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 88,
                    "pubMedId": 24124571,
                    "title": "Targeting wild-type and mutationally activated FGFR4 in rhabdomyosarcoma with the inhibitor ponatinib (AP24534).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24124571"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9168,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, sensitivity to Kisqali (ribociclib)-induced growth inhibition in fusion-positive, CDK4 overexpressing rhabdomyosarcoma cell lines reversely correlated with the expression level of Cdk4 in culture and in cell line xenograft models (PMID: 25810375).",
            "molecularProfile": {
                "id": 2527,
                "profileName": "CDK4 positive"
            },
            "therapy": {
                "id": 790,
                "therapyName": "Ribociclib",
                "synonyms": null
            },
            "indication": {
                "id": 3247,
                "name": "rhabdomyosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6979,
                    "pubMedId": 25810375,
                    "title": "CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25810375"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9169,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, sensitivity to Ibrance (palbociclib)-induced growth inhibition in fusion-positive, CDK4 over-expresssing rhabdomyosarcoma cell lines reversly correlated with the expression level of Cdk4 in culture (PMID: 25810375).",
            "molecularProfile": {
                "id": 2527,
                "profileName": "CDK4 positive"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 3247,
                "name": "rhabdomyosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6979,
                    "pubMedId": 25810375,
                    "title": "CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25810375"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11181,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Balversa (erdafitinib) inhibited proliferation of a rhabdomyosarcoma cell line with FGFR4 amplification in culture, and inhibited tumor growth in xenograft models (PMID: 28341788).",
            "molecularProfile": {
                "id": 3330,
                "profileName": "FGFR4 amp"
            },
            "therapy": {
                "id": 1028,
                "therapyName": "Erdafitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3247,
                "name": "rhabdomyosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9140,
                    "pubMedId": 28341788,
                    "title": "Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28341788"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11208,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TAS4464 inhibited growth and induced apoptosis in rhabdomyosarcoma cell lines in culture, resulted in tumor suppression in cell line xenograft models (Cancer Res 2016;76(14 Suppl):Abstract nr 3777).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5897,
                "therapyName": "TAS4464",
                "synonyms": null
            },
            "indication": {
                "id": 3247,
                "name": "rhabdomyosarcoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9152,
                    "pubMedId": null,
                    "title": "TAS4464, a novel and highly potent NEDD8 activating enzyme (NAE) inhibitor, causes apoptosis of sarcomas via cell cycle dysregulation",
                    "url": "http://cancerres.aacrjournals.org/content/76/14_Supplement/3777"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11751,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Prexasertib (LY2606368) decreased proliferation of several pediatric tumor cell lines in culture, including rhabdomyosarcoma cell lines (PMID: 28270495).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1651,
                "therapyName": "Prexasertib",
                "synonyms": null
            },
            "indication": {
                "id": 3247,
                "name": "rhabdomyosarcoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9764,
                    "pubMedId": 28270495,
                    "title": "The Checkpoint Kinase 1 Inhibitor Prexasertib Induces Regression of Preclinical Models of Human Neuroblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28270495"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 13092,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, rhabdomyosarcoma cell lines with high FGFR4 expression due to a PAX3-FOXO1 fusion demonstrated sensitivity to growth inhibition by H3B-6527 in culture (PMID: 29247039).",
            "molecularProfile": {
                "id": 28909,
                "profileName": "PAX3 - FOXO1 FGFR4 over exp"
            },
            "therapy": {
                "id": 6610,
                "therapyName": "H3B-6527",
                "synonyms": null
            },
            "indication": {
                "id": 3247,
                "name": "rhabdomyosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10667,
                    "pubMedId": 29247039,
                    "title": "H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29247039"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14132,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination therapy of Alpelisib (BYL719) and Binimetinib (MEK162) led to a synergistic effect in rhabdomyosarcoma cells harboring NRAS Q61H, demonstrating cell death in culture (PMID: 29437705).",
            "molecularProfile": {
                "id": 3374,
                "profileName": "NRAS Q61H"
            },
            "therapy": {
                "id": 1311,
                "therapyName": "Alpelisib + Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 3247,
                "name": "rhabdomyosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11474,
                    "pubMedId": 29437705,
                    "title": "NRAS-Mutated Rhabdomyosarcoma Cells Are Vulnerable to Mitochondrial Apoptosis Induced by Coinhibition of MEK and PI3K\u03b1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29437705"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20250,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SP-2509 treatment inhibited viability of rhabdomyosarcoma cell lines in culture (PMID: 29997151).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 9301,
                "therapyName": "SP-2509",
                "synonyms": null
            },
            "indication": {
                "id": 3247,
                "name": "rhabdomyosarcoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 17780,
                    "pubMedId": 29997151,
                    "title": "Therapeutic Targeting of KDM1A/LSD1 in Ewing Sarcoma with SP-2509 Engages the Endoplasmic Reticulum Stress Response.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29997151"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT00084695",
            "title": "Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases",
            "phase": "Phase II",
            "recruitment": "Unknown status",
            "therapies": [
                {
                    "id": 1166,
                    "therapyName": "Fludarabine",
                    "synonyms": null
                },
                {
                    "id": 2558,
                    "therapyName": "Busulfan + Melphalan",
                    "synonyms": null
                },
                {
                    "id": 1844,
                    "therapyName": "anti-thymocyte globulin",
                    "synonyms": null
                },
                {
                    "id": 1148,
                    "therapyName": "Cyclophosphamide",
                    "synonyms": null
                },
                {
                    "id": 2188,
                    "therapyName": "Prednisone",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01241162",
            "title": "Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 650,
                    "therapyName": "Decitabine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01331135",
            "title": "Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 917,
                    "therapyName": "Sirolimus",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01446809",
            "title": "Pazopanib Hydrochloride Followed By Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1472,
                    "therapyName": "Doxorubicin + Ifosfamide",
                    "synonyms": null
                },
                {
                    "id": 1471,
                    "therapyName": "Doxorubicin + Ifosfamide + Pazopanib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01518413",
            "title": "Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1323,
                    "therapyName": "Irinotecan + Sorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01661400",
            "title": "Anti-Angiogenic Therapy Post Transplant (ASCR) for Relapsed and Refractory Pediatric Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1148,
                    "therapyName": "Cyclophosphamide",
                    "synonyms": null
                },
                {
                    "id": 1475,
                    "therapyName": "Thalidomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01871766",
            "title": "Treatment of Localized Rhabdomyosarcoma With Chemotherapy, Radiotherapy, and Surgery",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1119,
                    "therapyName": "Bevacizumab + Cyclophosphamide + Sorafenib",
                    "synonyms": null
                },
                {
                    "id": 1436,
                    "therapyName": "Dactinomycin + Vincristine",
                    "synonyms": null
                },
                {
                    "id": 1435,
                    "therapyName": "Cyclophosphamide + Dactinomycin + Vincristine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02013336",
            "title": "Phase 1 Study of MM-398 Plus Cyclophosphamide in Pediatric Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7579,
                    "therapyName": "Cyclophosphamide + MM-398",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02095132",
            "title": "Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1361,
                    "therapyName": "Adavosertib + Irinotecan",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02100891",
            "title": "Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                
            ]
        },
        {
            "nctId": "NCT02303028",
            "title": "Phase I Dose Escalation Study of Topotecan and Pazopanib in Children With Recurrent/Refractory Solid and CNS Tumours",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1469,
                    "therapyName": "Pazopanib + Topotecan",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02304458",
            "title": "Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1627,
                    "therapyName": "Ipilimumab + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02372006",
            "title": "Trial of Afatinib in Pediatric Tumours",
            "phase": "Phase Ib/II",
            "recruitment": "Suspended",
            "therapies": [
                {
                    "id": 623,
                    "therapyName": "Afatinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02390752",
            "title": "PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN)",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 874,
                    "therapyName": "Pexidartinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02446431",
            "title": "Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1148,
                    "therapyName": "Cyclophosphamide",
                    "synonyms": null
                },
                {
                    "id": 667,
                    "therapyName": "Bevacizumab",
                    "synonyms": null
                },
                {
                    "id": 936,
                    "therapyName": "Temsirolimus",
                    "synonyms": null
                },
                {
                    "id": 1076,
                    "therapyName": "Valproic acid",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02567435",
            "title": "Combination Chemotherapy and Irinotecan Hydrochloride or Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1435,
                    "therapyName": "Cyclophosphamide + Dactinomycin + Vincristine",
                    "synonyms": null
                },
                {
                    "id": 936,
                    "therapyName": "Temsirolimus",
                    "synonyms": null
                },
                {
                    "id": 1074,
                    "therapyName": "Irinotecan",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02574728",
            "title": "Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3143,
                    "therapyName": "Celecoxib + Cyclophosphamide + Etoposide + Sirolimus",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02644460",
            "title": "Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 802,
                    "therapyName": "Abemaciclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02789228",
            "title": "Research Study Utilizing Expanded Multi-antigen Specific Lymphocytes for the Treatment of Solid Tumors (REST)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9602,
                    "therapyName": "MultiTAA-specific T cells",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02867592",
            "title": "Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 998,
                    "therapyName": "Cabozantinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02890758",
            "title": "Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3060,
                    "therapyName": "ALT-803",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02982941",
            "title": "Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2863,
                    "therapyName": "MGA271",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03139331",
            "title": "PAZIT Study for Children and Young Adults With Relapsed or Refractory Sarcoma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 5635,
                    "therapyName": "Irinotecan + Pazopanib + Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03155620",
            "title": "Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2683,
                    "therapyName": "Tazemetostat",
                    "synonyms": null
                },
                {
                    "id": 2650,
                    "therapyName": "Larotrectinib",
                    "synonyms": null
                },
                {
                    "id": 1069,
                    "therapyName": "LY3023414",
                    "synonyms": null
                },
                {
                    "id": 342,
                    "therapyName": "Vemurafenib",
                    "synonyms": null
                },
                {
                    "id": 850,
                    "therapyName": "Palbociclib",
                    "synonyms": null
                },
                {
                    "id": 837,
                    "therapyName": "Olaparib",
                    "synonyms": null
                },
                {
                    "id": 997,
                    "therapyName": "Ulixertinib",
                    "synonyms": null
                },
                {
                    "id": 1028,
                    "therapyName": "Erdafitinib",
                    "synonyms": null
                },
                {
                    "id": 913,
                    "therapyName": "Selumetinib",
                    "synonyms": null
                },
                {
                    "id": 961,
                    "therapyName": "Ensartinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03210714",
            "title": "Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1028,
                    "therapyName": "Erdafitinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03213678",
            "title": "PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1069,
                    "therapyName": "LY3023414",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03213704",
            "title": "Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2650,
                    "therapyName": "Larotrectinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03221400",
            "title": "PEN-866 in Patients With Advanced Solid Malignancies",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4842,
                    "therapyName": "STA-8666",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03233204",
            "title": "Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 837,
                    "therapyName": "Olaparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03245151",
            "title": "Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1713,
                    "therapyName": "Everolimus + Lenvatinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03441360",
            "title": "Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Subjects With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 728,
                    "therapyName": "Eribulin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03458728",
            "title": "Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 995,
                    "therapyName": "Copanlisib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03698994",
            "title": "Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 997,
                    "therapyName": "Ulixertinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03709680",
            "title": "Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8371,
                    "therapyName": "Irinotecan + Palbociclib + Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04095221",
            "title": "A Study of the Drugs Prexasertib, Irinotecan, and Temozolomide in People With Desmoplastic Small Round Cell Tumor and Rhabdomyosarcoma",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8753,
                    "therapyName": "Irinotecan + Prexasertib + Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04299113",
            "title": "Mocetinostat With Vinorelbine in Children, Adolescents & Young Adults With Refractory and/or Recurrent Rhabdomyosarcoma",
            "phase": "Phase I",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 9465,
                    "therapyName": "Mocetinostat + Vinorelbine",
                    "synonyms": null
                }
            ]
        }
    ]
}